Clinical Trial: Treatment Protocol for Clofazamine in the Long Term Treatment of Leprosy

Study Status: No longer available
Recruit Status: No longer available
Study Type: Expanded Access

Official Title: Clofazamine in the Long Term Treatment of Leprosy, Phase III

Brief Summary: Clofazimine has shown effectiveness in the treatment of leprosy for many years. The World Health Organization and the National Hansen's Disease Program consider clofazamine to be standard therapy for treatment of multibacillary leprosy. In recent years, the availability of the drug has become limited and is currently available only under a research protocol and is considered "investigational." Use of Clofazamine in patients presenting with lepromatous leprosy is necessary for patients exhibiting nerve involvement or lesions resistant to other therapies. This drug will be used prospectively for patients who require treatment of leprosy as deemed appropriate by a Kaiser Permanente Southern California physician.

Detailed Summary: Treatment protocol objective is to treat patients with clofazamine who meet inclusion criteria stated above.
Sponsor: Kaiser Permanente

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Kaiser Permanente

Dates:
Date Received: February 26, 2009
Date Started:
Date Completion:
Last Updated: April 2, 2015
Last Verified: March 2015